ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
![](https://exevir.com/wp-content/uploads/2024/06/onder-ortel-fRsGpNMK394_small-1024x683.jpg)
Photo by Önder Örtel on Unsplash
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
![](https://exevir.com/wp-content/uploads/2024/01/186137856_l-1024x683.jpg)
ExeVir Bio Appoints a Chief Scientific Officer
![](https://exevir.com/wp-content/uploads/2023/09/ExeVir_Trinity-1024x576.png)
Ghent, Belgium, 1 September 2023: ExeVir Bio, a biotech company developing robust single-domain antibody therapies for broad protection against infectious diseases, today announced Dr. Viki Bockstal as its Chief Scientific Officer (CSO) and Caroline Sagaert as its Head of Operations. Jean-Philippe Bultot will become the Company’s Head of Finance and lead ExeVir’s finance and accounting. […]
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
![](https://exevir.com/wp-content/uploads/2023/06/pexels-pixabay-86722-1024x678.jpg)
Dengue is a mosquito borne viral infection listed by WHO as top 10 threat for global health
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO)
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
![](https://exevir.com/wp-content/uploads/2023/03/IC-1024x640.png)
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike
Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
![](https://exevir.com/wp-content/uploads/2023/01/Picture_ExeVir_EIB.jpg)
xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing agreement of up to EUR 25M (around USD 26.5m) with the European Investment Bank (EIB)*. The EIB financing will help advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19.
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
![](https://exevir.com/wp-content/uploads/2022/10/Dr_Bolger_sq.jpg)
ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors.
Dr. Bolger has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development and Venture Investments at Johnson & Johnson Innovation – JJDC and at GlaxoSmithKline.
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
![](https://exevir.com/wp-content/uploads/2021/09/images.jpeg)
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.
ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody
![](https://exevir.com/wp-content/uploads/2021/08/Pic-2-1024x602.jpeg)
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
![](https://exevir.com/wp-content/uploads/2021/07/vuistje.jpg)
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.